Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial
- Wednesday, April 6, 2022, 7:13
- Business
- Add a comment
AUSTIN, Texas , April 6, 2022 /PRNewswire/ — Direct Biologics, a regenerative biotechnology company with a lifesaving mesenchymal stem cell (MSC) derived extracellular vesicle (EV) platform technology, announces topline results from its first-in-human, multicenter, Phase II double-blind,…
About the Author
adminasapcorp has written 41302 stories on this site.